BMC Cancer · 2019 · 61 citations · 38 references
MedicineOncologyPathologyGynecologic OncologyMetastasisTumor MicroenvironmentCancer BiomarkersCancer TranscriptomicsCancer-associated FibroblastsHematogenous MetastasisMolecular Tumor ProfilingTumor-stroma InteractionsCancer Metastasis BiomarkersMetastatic Signature DiscoveryOvarian Cancer BiomarkersOvarian Cancer MetastasisOvarian Cancer Prognostic BiomarkersOvarian Tumor BiomarkersSerous Ovarian TumorsStromal Cell Activation
BACKGROUND: The clinical significance of hematogenous and lymphatic metastasis in ovarian cancer has been increasingly addressed, as it plays an imperative role in the formation of both intraperitoneal and distant metastases. Our objective is to identify the key molecules and biological processes potentially related to this relatively novel metastatic route in serous ovarian cancer. METHODS: Since lymphovascular space invasion (LVSI) is considered as the first step of hematogenous and lymphatic dissemination, we developed a gene signature mainly based on the transcriptome profiles with available information on LVSI status in the Cancer Genome Atlas (TCGA) dataset. We then explored the underlying biological rationale and prognostic value of the identified gene signature using multiple public databases. RESULTS: We observe that primary tumors with increased risk of hematogenous and lymphatic metastasis highly express a panel of genes, namely POSTN, LUM, THBS2, COL3A1, COL5A1, COL5A2, FAP1 and FBN1. The identified geneset is characterized by enhanced deposition of extracellular matrix and extensive stromal activation. Mechanistically, both the recruitment and the activation of stromal cells, especially fibroblasts, are closely associated with lymphovascular metastasis. Survival analysis further reveals that the elevated expression of the identified genes correlates to cancer progression and poor prognosis in patients with serous ovarian cancer. CONCLUSIONS: Our findings indicate that tumor stroma supports the hematogenous and lymphatic spread of ovarian cancer, increasing tumor invasiveness and ultimately resulting in worse survival. Thus stroma-targeted therapies may improve the clinical outcomes in combination with cytoreductive surgery and chemotherapy.
38
clusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters
Guangchuang Yu, Li-Gen Wang, Yanyan Han et al. · OMICS A Journal of Integrative Biology · 2012 · 38.3K citations
Inferring tumour purity and stromal and immune cell admixture from expression data
Kosuke Yoshihara, Maria Shahmoradgoli, Emmanuel Martínez et al. · Nature Communications · 2013 · 10.7K citations · Full text
Integrated genomic analyses of ovarian carcinoma
Debra Bell, Andrew Berchuck, Narciso Olvera et al. · Nature · 2011 · 8.2K citations · Full text
TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells
Taiwen Li, Jing‐Yu Fan, Binbin Wang et al. · Cancer Research · 2017 · 6.6K citations · Full text
Life Sciences, Immunology, Oncology +17